FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043295630> ?p ?o ?g. }

• W2043295630 endingPage "864" @default.
• W2043295630 startingPage "857" @default.
• W2043295630 abstract "Phoradendron serotinum is commonly used in Mexican traditional medicine for the empirical treatment of cancer. However, there are no studies regarding the antitumoral or immunomodulatory activities of Phoradendron serotinum. The in vivo toxicity of ethanolic extracts of Phoradendron serotinum (PSE) was evaluated in mice according to the Lorke procedure. The in vitro immunomodulatory effects of PSE were evaluated estimating the effects of PSE on the pinocytosis, NO production and lysosomal enzyme activity in murine macrophages RAW 264.7. The effects of PSE on the proliferation of murine splenocytes and NK cell activity were also assayed. The cytotoxic effects on TC-1 (lung murine cancer cells) were evaluated using the MTT assay, whereas the apoptotic effect of PSE on TC-1 cells was evaluated using TUNEL assay. Also, different doses of PSE were injected intraperitoneally daily into C57BL/6 mice bearing tumors of TC-1 cells during 25 days. The growth and weight of tumors was measured. In addition, the levels of IL-2, IL-6, IL-12, IL-23 and IFN-γ in murine serum and supernatants of K562 cell—murine splenocyte cocultures were measured. PSE stimulated the proliferation, pinocytosis and lysosomal enzyme activity in murine macrophages with a similar potency than lypopolisaccharides 1 μg/ml. In addition, PSE stimulated the proliferation of murine splenocytes and induced the NK cell activity. PSE showed cytotoxic (IC50 = 1.9 μg/ml) and apoptotic effects against TC-1 cells. The LD50 was 125 mg/kg by intraperitoneal route (i.p.) and 375 mg/kg by oral route. PSE administrated at 1, 5 and 10 mg/kg i.p. inhibited the tumor growth by 18%, 40% and 69%, respectively, in mice bearing TC-1 tumor. PSE increased the in vitro and in vivo release of IL-2, IL-6 and IFN-γ but lacked effect on IL-12 and IL-23 release. Phoradendron serotinum shows moderate toxic effects in vivo, exerts cytotoxic and apoptotic effects on TC-1 cells. Phoradendron serotinum also has antitumor effects in mice bearing TC-1 tumor and induces immunomodulatory activities in vivo. The results suggest that antitumoral effects of PSE are related with the production of immunity-related cytokines." @default.
• W2043295630 created "2016-06-24" @default.
• W2043295630 creator A5000762110 @default.
• W2043295630 creator A5025062514 @default.
• W2043295630 creator A5043852379 @default.
• W2043295630 creator A5049939191 @default.
• W2043295630 creator A5053872194 @default.
• W2043295630 creator A5065721170 @default.
• W2043295630 creator A5066251849 @default.
• W2043295630 creator A5073398392 @default.
• W2043295630 creator A5085569647 @default.
• W2043295630 date "2012-08-01" @default.
• W2043295630 modified "2023-10-18" @default.
• W2043295630 title "The antitumoral effect of the American mistletoe Phoradendron serotinum (Raf.) M.C. Johnst. (Viscaceae) is associated with the release of immunity-related cytokines" @default.
• W2043295630 cites W1123722611 @default.
• W2043295630 cites W122940189 @default.
• W2043295630 cites W1546288178 @default.
• W2043295630 cites W1966916298 @default.
• W2043295630 cites W1984084573 @default.
• W2043295630 cites W1995330034 @default.
• W2043295630 cites W2022350668 @default.
• W2043295630 cites W2039638372 @default.
• W2043295630 cites W2042464457 @default.
• W2043295630 cites W2055243849 @default.
• W2043295630 cites W2069622125 @default.
• W2043295630 cites W2113920410 @default.
• W2043295630 cites W2115855176 @default.
• W2043295630 cites W2130138623 @default.
• W2043295630 cites W2137450012 @default.
• W2043295630 cites W2142208636 @default.
• W2043295630 cites W2144229582 @default.
• W2043295630 cites W2147212007 @default.
• W2043295630 cites W2158153035 @default.
• W2043295630 cites W2162621782 @default.
• W2043295630 cites W2214909216 @default.
• W2043295630 cites W2327980512 @default.
• W2043295630 doi "https://doi.org/10.1016/j.jep.2012.06.018" @default.
• W2043295630 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22732726" @default.
• W2043295630 hasPublicationYear "2012" @default.
• W2043295630 type Work @default.
• W2043295630 sameAs 2043295630 @default.
• W2043295630 citedByCount "16" @default.
• W2043295630 countsByYear W20432956302013 @default.
• W2043295630 countsByYear W20432956302014 @default.
• W2043295630 countsByYear W20432956302016 @default.
• W2043295630 countsByYear W20432956302017 @default.
• W2043295630 countsByYear W20432956302020 @default.
• W2043295630 countsByYear W20432956302021 @default.
• W2043295630 countsByYear W20432956302022 @default.
• W2043295630 countsByYear W20432956302023 @default.
• W2043295630 crossrefType "journal-article" @default.
• W2043295630 hasAuthorship W2043295630A5000762110 @default.
• W2043295630 hasAuthorship W2043295630A5025062514 @default.
• W2043295630 hasAuthorship W2043295630A5043852379 @default.
• W2043295630 hasAuthorship W2043295630A5049939191 @default.
• W2043295630 hasAuthorship W2043295630A5053872194 @default.
• W2043295630 hasAuthorship W2043295630A5065721170 @default.
• W2043295630 hasAuthorship W2043295630A5066251849 @default.
• W2043295630 hasAuthorship W2043295630A5073398392 @default.
• W2043295630 hasAuthorship W2043295630A5085569647 @default.
• W2043295630 hasConcept C109316439 @default.
• W2043295630 hasConcept C1491633281 @default.
• W2043295630 hasConcept C153911025 @default.
• W2043295630 hasConcept C154317977 @default.
• W2043295630 hasConcept C185592680 @default.
• W2043295630 hasConcept C189976730 @default.
• W2043295630 hasConcept C190283241 @default.
• W2043295630 hasConcept C202751555 @default.
• W2043295630 hasConcept C203014093 @default.
• W2043295630 hasConcept C2780783641 @default.
• W2043295630 hasConcept C28005876 @default.
• W2043295630 hasConcept C40017333 @default.
• W2043295630 hasConcept C55493867 @default.
• W2043295630 hasConcept C62112901 @default.
• W2043295630 hasConcept C86803240 @default.
• W2043295630 hasConcept C98274493 @default.
• W2043295630 hasConceptScore W2043295630C109316439 @default.
• W2043295630 hasConceptScore W2043295630C1491633281 @default.
• W2043295630 hasConceptScore W2043295630C153911025 @default.
• W2043295630 hasConceptScore W2043295630C154317977 @default.
• W2043295630 hasConceptScore W2043295630C185592680 @default.
• W2043295630 hasConceptScore W2043295630C189976730 @default.
• W2043295630 hasConceptScore W2043295630C190283241 @default.
• W2043295630 hasConceptScore W2043295630C202751555 @default.
• W2043295630 hasConceptScore W2043295630C203014093 @default.
• W2043295630 hasConceptScore W2043295630C2780783641 @default.
• W2043295630 hasConceptScore W2043295630C28005876 @default.
• W2043295630 hasConceptScore W2043295630C40017333 @default.
• W2043295630 hasConceptScore W2043295630C55493867 @default.
• W2043295630 hasConceptScore W2043295630C62112901 @default.
• W2043295630 hasConceptScore W2043295630C86803240 @default.
• W2043295630 hasConceptScore W2043295630C98274493 @default.
• W2043295630 hasFunder F4320310066 @default.
• W2043295630 hasFunder F4320321739 @default.
• W2043295630 hasIssue "3" @default.
• W2043295630 hasLocation W20432956301 @default.
• W2043295630 hasLocation W20432956302 @default.
• W2043295630 hasOpenAccess W2043295630 @default.

• next